One year ago millions of stout Americans were waiting to hear if or not the Chuck and Drugs Agency would convey approval to the diet drug rimonabant (Acomplia). Obviously there was vast disappointment when this approval was not given. Rimonabant never truly prepared it to the American mart although it is contemplation that the patent holder testament send for another bite of the cherry at a adjacent date, armed with deeper clinical probation data.

There is, therefore, a extended deal provided excitement over Merck's latest diet drug taranabant. The results from the moment event of testing were encouraging and promptly after another two agedness of testing it seems that the results for episode three may be equally exciting, though the ending announcement is even to be published.

Researchers announced that scan participants fascinating varying doses of taranabant at sea 8 to 14 pounds over a 12-week period. There was one question, however, which all the more remains unanswered. Does taranabant admit less indicative side stuff than rimonabant? Both drugs job in a coincidental way, by targeting specific receptors in the brain. Acomplia, however, was not approved by the FDA after concerns were raised over its psychiatric side baggage which may build depression and suicidal thoughts in patients prone to intellectual health problems. So how does taranabant compare? Initial feedback seems to propose that between one-fifth and one-third of patients had experienced adverse side belongings which included depressed mood, irritability, anger, temper swings and insomnia. Unlike rimonabant, however, patients reported no suicidal thoughts though it was conceded that the third degree had not been asked in a systematic way.

There will, of course, compass to be extended conclusive evidence if before the FDA grants approval to the original drug. The society expects the leaf III report to be published next this year and for taranabant to be submitted for FDA approval before the location of 2008. Taranabant will extremely be submitted to the European Medicines Agency although it is believed that Merck wants to gratify it approved in the US first.